GE HealthCare stock holds firm as results stay central

GE HealthCare (ISIN US36266G1076) stays tied to its latest reported operating trends, with the company posting revenue of $19.6 billion in fiscal 2025, adjusted EBIT margin of 16.2%, and free cash flow of $1.9 billion. Those figures frame GE HealthCare stock even without a fresh market-moving headline in the available evidence.

Revenue and margin stay central

The most recent year-end numbers show why the company remains on screens: revenue reached $19.6 billion in fiscal 2025, while adjusted EBIT margin stood at 16.2% and free cash flow totaled $1.9 billion. The comparison matters because it gives investors a quantified read on profitability and cash generation, not just sales growth.

Those metrics also set a baseline for the next reporting period. For a healthcare equipment group, margin and cash flow usually matter as much as top-line growth, because they show whether product mix and cost discipline are holding up.

Fiscal 2025 sets the base

The company’s fiscal 2025 revenue of $19.6 billion provides the clearest reference point in the current evidence set, while $1.9 billion in free cash flow indicates that earnings translated into actual liquidity. The 16.2% adjusted EBIT margin is the key comparison point for any later quarter, because a move of even a few percentage points would change the earnings picture materially.

That mix of numbers also gives a simple investor lens: revenue, margin, and cash generation are all moving parts that can be tracked against future quarterly disclosures. A business with this profile tends to trade on execution rather than on story alone.

Product line matters again

GE HealthCare’s product mix remains relevant because the company sells imaging, patient care, and pharmaceutical diagnostics systems, and that portfolio is what turns the annual numbers into a repeatable operating model. In the latest disclosed year, the business scale and cash generation suggest that installed base, service revenue, and equipment demand are still the core drivers.

If the next report shows a change in margin or cash conversion, the market will likely read it through that product mix. That is especially true for an equipment supplier where replacement cycles and service contracts can smooth results over time.

Stock view near reporting

GE HealthCare stock is best read against those annual figures until a new period changes the frame. The company is still measured by whether revenue holds near $19.6 billion, margin stays near 16.2%, and free cash flow remains close to $1.9 billion.

A dated market price was not present in the available evidence, so the most concrete current anchor is the fiscal 2025 operating set. That leaves the next earnings cycle as the natural point where price and fundamentals can be compared again.